Skip to main content

Table 3 Potential factors associated with HCC

From: Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study

High-risk vs. low-risk

 

Univariate

Multivariate

 

p value

OR

95% CI

p value

OR

95% CI

THRI

0.001

1.015

1.006–1.024

0.035

1.026

1.002–1.051

BMI

0.266

1.063

0.954–1.184

0.778

1.042

0.784–1.383

ALT

0.352

1.001

0.999–1.003

0.714

1.010

0.958–1.065

AST

0.420

1.001

0.998–1.004

0.089

1.045

0.993–1.099

GGT

0.198

0.998

0.994–1.001

0.293

0.994

0.982–1.005

ALB

0.878

1.004

0.956–1.054

0.394

1.097

0.886–1.359

TBil

0.930

1.000

0.991–1.008

0.328

0.960

0.885–1.042

Cr

0.376

0.996

0.987–1.005

0.775

0.990

0.927–1.058

AFP

0.021

1.022

1.003–1.041

0.770

1.004

0.979–1.028

APRI

0.182

1.040

0.982–1.102

0.294

0.540

0.170–1.710

FIB-4

0.099

1.035

0.993–1.079

0.793

1.045

0.753–1.451

MELD

0.794

0.993

0.938–1.050

0.713

0.920

0.589–1.436

Child-Pugh Score

0.714

1.035

0.863–1.241

0.068

4.269

0.896–20.330

Intermediate-risk vs. Low-risk

 

Univariate

Multivariate

 

p value

OR

95% CI

p value

OR

95% CI

THRI

0.101

1.010

0.998–1.023

0.692

1.012

0.954–1.074

BMI

0.696

1.033

0.877–1.217

0.881

1.041

0.612–1.773

ALT

0.505

0.996

0.986–1.007

0.679

0.972

0.848–1.113

AST

0.458

0.996

0.985–1.007

0.846

1.016

0.869–1.187

GGT

0.549

0.999

0.995–1.002

0.144

1.015

0.995–1.035

ALB

0.992

1.000

0.929–1.077

0.076

1.972

0.931–4.176

TBil

0.520

0.996

0.983–1.009

0.866

0.958

0.580–1.582

Cr

0.588

1.002

0.996–1.007

0.410

0.928

0.777–1.109

AFP

0.922

1.000

0.990–1.009

0.973

1.002

0.907–1.107

APRI

0.390

0.883

0.665–1.173

0.213

0.044

0.000–5.946

FIB-4

0.392

0.958

0.867–1.058

0.105

3.604

0.766–16.965

MELD

0.621

1.020

0.944–1.102

0.814

1.162

0.333–4.051

Child-Pugh Score

0.752

1.048

0.784–1.402

0.158

20.454

0.309–1355.822

  1. OR odds ratio, CI confidence interval, THRI Toronto hepatocellular carcinoma risk index, BMI body mass index, INR international normalized ratio, PT prothrombin time, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, ALB albumin, TBil total bilirubin, Cr creatinine, AFP alpha fetoprotein, APRI AST to platelet ratio index, FIB-4 Fibrosis-4 score, MELD model for end-stage liver disease
  2. The italicized data were statistically significant